368 related articles for article (PubMed ID: 15742464)
21. TNF-alpha antagonists: pulmonary legionellosis.
Prescrire Int; 2007 Feb; 16(87):20. PubMed ID: 17326282
[TBL] [Abstract][Full Text] [Related]
22. Cutaneous adverse events during treatment of chronic inflammatory rheumatic conditions with tumor necrosis factor antagonists: study using the Spanish registry of adverse events of biological therapies in rheumatic diseases.
Hernández MV; Sanmartí R; Cañete JD; Descalzo MA; Alsina M; Carmona L; Gomez-Reino JJ;
Arthritis Care Res (Hoboken); 2013 Dec; 65(12):2024-31. PubMed ID: 23926075
[TBL] [Abstract][Full Text] [Related]
23. Schnitzler's syndrome--exacerbation after anti-TNF treatment.
Thonhofer R; Uitz E; Graninger W
Rheumatology (Oxford); 2007 Jun; 46(6):1041-2. PubMed ID: 17449490
[No Abstract] [Full Text] [Related]
24. Onset of psoriasis during treatment with TNF-{alpha} antagonists: a report of 3 cases.
Ubriani R; Van Voorhees AS
Arch Dermatol; 2007 Feb; 143(2):270-2. PubMed ID: 17310016
[No Abstract] [Full Text] [Related]
25. ["MGUS": a potentially under diagnosed event during anti-TNF-α treatment of psoriasis?].
Schmutz JL; Trechot P
Ann Dermatol Venereol; 2013 Feb; 140(2):157-8. PubMed ID: 23395504
[No Abstract] [Full Text] [Related]
26. Incidence of tuberculosis in Korean patients with rheumatoid arthritis (RA): effects of RA itself and of tumor necrosis factor blockers.
Seong SS; Choi CB; Woo JH; Bae KW; Joung CL; Uhm WS; Kim TH; Jun JB; Yoo DH; Lee JT; Bae SC
J Rheumatol; 2007 Apr; 34(4):706-11. PubMed ID: 17309133
[TBL] [Abstract][Full Text] [Related]
27. Comparison of drug retention rates and causes of drug discontinuation between anti-tumor necrosis factor agents in rheumatoid arthritis.
Du Pan SM; Dehler S; Ciurea A; Ziswiler HR; Gabay C; Finckh A;
Arthritis Rheum; 2009 May; 61(5):560-8. PubMed ID: 19405000
[TBL] [Abstract][Full Text] [Related]
28. Anti-TNF-alpha therapies: they are all the same (aren't they?).
Mpofu S; Fatima F; Moots RJ
Rheumatology (Oxford); 2005 Mar; 44(3):271-3. PubMed ID: 15561736
[No Abstract] [Full Text] [Related]
29. [Non tuberculous anti-TNF associated opportunistic infections].
Marie I; Guglielmino E
Rev Med Interne; 2010 May; 31(5):353-60. PubMed ID: 20381217
[TBL] [Abstract][Full Text] [Related]
30. Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor alpha therapies: does the risk change with the time since start of treatment?
Askling J; van Vollenhoven RF; Granath F; Raaschou P; Fored CM; Baecklund E; Dackhammar C; Feltelius N; Cöster L; Geborek P; Jacobsson LT; Lindblad S; Rantapää-Dahlqvist S; Saxne T; Klareskog L
Arthritis Rheum; 2009 Nov; 60(11):3180-9. PubMed ID: 19877027
[TBL] [Abstract][Full Text] [Related]
31. Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists.
Carmona L; Gómez-Reino JJ; Rodríguez-Valverde V; Montero D; Pascual-Gómez E; Mola EM; Carreño L; Figueroa M;
Arthritis Rheum; 2005 Jun; 52(6):1766-72. PubMed ID: 15934089
[TBL] [Abstract][Full Text] [Related]
32. [Guidelines of the Israeli association of rheumatology for the prevention of tuberculosis in patients treated with TNF-alpha blockers].
Elkayam O; Balbir-Gurman A; Lidgi M; Rahav G; Weiler-Ravel D
Harefuah; 2007 Mar; 146(3):235-7, 244. PubMed ID: 17460934
[TBL] [Abstract][Full Text] [Related]
33. [Systematic review: safety and efficacy of anti-TNF in elderly patients].
Busquets N; Carmona L; Surís X
Reumatol Clin; 2011; 7(2):104-12. PubMed ID: 21794793
[TBL] [Abstract][Full Text] [Related]
34. The use of anti-tumour necrosis factor therapy in HIV-positive individuals with rheumatic disease.
Cepeda EJ; Williams FM; Ishimori ML; Weisman MH; Reveille JD
Ann Rheum Dis; 2008 May; 67(5):710-2. PubMed ID: 18079191
[TBL] [Abstract][Full Text] [Related]
35. Sarcoidosis during anti-tumor necrosis factor-alpha therapy: no relapse after rechallenge.
van der Stoep D; Braunstahl GJ; van Zeben J; Wouters J
J Rheumatol; 2009 Dec; 36(12):2847-8. PubMed ID: 19966199
[No Abstract] [Full Text] [Related]
36. Tuberculosis in anti-TNF-α treated patients remains a problem in countries with an intermediate incidence: analysis of 25 patients matched with a control population.
Abreu C; Magro F; Santos-Antunes J; Pilão A; Rodrigues-Pinto E; Bernardes J; Bernardo A; Magina S; Vilas-Boas F; Lopes S; Macedo G; Sarmento A
J Crohns Colitis; 2013 Nov; 7(10):e486-92. PubMed ID: 23583099
[TBL] [Abstract][Full Text] [Related]
37. Tumour necrosis factor-alpha and tuberculosis: guidance from the National TB Advisory Committee.
Kavanagh PM; Gilmartin JJ; O'Donnell J; O'Flanagan D
Ir Med J; 2008 Jan; 101(1):6-7. PubMed ID: 18369014
[No Abstract] [Full Text] [Related]
38. Lack of adverse effect of anti-tumor necrosis factor-α biologics in treatment of rheumatoid arthritis: 5 years follow-up.
Dewedar AM; Shalaby MA; Al-Homaid S; Mahfouz AM; Shams OA; Fathy A
Int J Rheum Dis; 2012 Jun; 15(3):330-5. PubMed ID: 22709496
[TBL] [Abstract][Full Text] [Related]
39. Tumor necrosis factor inhibitors block apoptosis of human epithelial cells of the salivary glands.
Sisto M; D'Amore M; Caprio S; Mitolo V; Scagliusi P; Lisi S
Ann N Y Acad Sci; 2009 Aug; 1171():407-14. PubMed ID: 19723083
[TBL] [Abstract][Full Text] [Related]
40. Coxiella burnetii infection (Q fever) in rheumatoid arthritis patients with and without anti-TNFα therapy.
Schoffelen T; Kampschreur LM; van Roeden SE; Wever PC; den Broeder AA; Nabuurs-Franssen MH; Sprong T; Joosten LA; van Riel PL; Oosterheert JJ; van Deuren M; Creemers MC
Ann Rheum Dis; 2014 Jul; 73(7):1436-8. PubMed ID: 24794150
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]